You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

562 Results
Guidelines and Advice
Status: Current
ID: pet 2017-1
Dec 2017
Drug
Quick Link(s):
Patient Info Sheet
Jan 2018
Guidelines and Advice
Status: Current
Version: 1
Sep 2017
Blog post
This year, more than 90,000 people in Ontario will discover they have cancer. Approximately one in two Ontarians are expected to be diagnosed with...
Jan 2018
Guidelines and Advice
Status: Current
ID: GL 8-11
Jan 2018
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Endocrine, 
Gastrointestinal, 
Genitourinary, 
Gynecologic, 
Head and Neck, 
Hematologic, 
Lung, 
Sarcoma, 
Skin, 
Unknown Primary
Show More Show more tags
, Show Less Show fewer tags
Intent: Supportive Care, Palliative
Drugs Used:
pamidronate
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
nivolumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Document
Mar 2018
Document
Mar 2018
Document
Mar 2018

Pages